References
  1. Endo S, Takahashi G, Shozushima T, Matsumoto N, Kojika M, Suzuki Y, Inoue Y.
    Usefulness of Presepsin (soluble CD14 subtype) as a Diagnostic Marker for Sepsis, JJAAM. 2012; 23:27-28
  2. Shozushima T, Takahashi  G, Matsumoto N, Kojika M, Okamura Y, Endo S.
    Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011; 17(6):764-769
  3. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, Fukui Y, Tanaka K, Nojima T, Okamura Y.
    Uselfulness of Presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012; 18(6):891-897
  4. Spanuth E, Wilhelm J, Loppnow H, Ebelt H, Ivandic B, Werdan K. (2012).
    Diagnostic and Prognostic Value of Presepsin (Soluble CD14 Subtype) in Emergency Patients with Early Sepsis Using the New Assay PATHFAST Presepsin. In Renz. H & Tauber. R (Ed.) Advances in Clinical Chemistry and Laboratory Medicine (pp.128-133). Berlin/Boston: De Gruyter
  5. Spanuth E, Ebelt H, Ivandic B, Werdan K.
    The new Sepsis Marker Presepsin is Superior for Prognosis and Disease Monitoring compared to Procalcitonin. Poster presented at the 20th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, Milan (Italy), May 19th – 22nd 2013
  6. Okamura Y, Yokoi H.
    Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clinica Chimica Acta. 2011; 412:2157-2161
  7. Internal data